Danimer Scientific price target raised to $7 from $6 at Piper Sandler

Piper Sandler analyst Charles Neivert raised the firm’s price target on Danimer Scientific to $7 from $6 and keeps an Overweight rating on the shares post the Q4 results and channel checks. The analyst believes there is now increasing clarity around the timing of product uptake, additional improvements in operational efficiency, a "significantly improved" cash position and the eventual disposition of a government loan, which would fund new capacity in Georgia. The firm says Danimer’s improving earnings clarity reduces the stock’s speculative risk.